BMS at the 64th ASH Annual Meeting & Exposition

Delivering transformative research across major hematologic diseases

INTENDED FOR U.S. SCIENTIFIC AUDIENCES ONLY.

Our data at the 2022 American Society of Hematology (ASH) Annual Meeting reinforce our commitment to transforming the lives of patients with blood cancers and disorders through science. We are excited to share data and research across a broad range of hematologic diseases, including multiple myeloma, lymphomas, leukemias and other blood disorders. 

Hear from Samit Hirawat, MD, executive vice president and chief medical officer, Global Drug Development, and Kristen Hege, MD, senior vice president, Early Clinical Development, about how our heritage and leadership in hematology uniquely position us to treat patients living with multiple myeloma and other hematologic diseases, now and in the future.

Myeloma Resources

Discover multiple myeloma resources for patients, caregivers and HCPs.

Our Data at ASH 

Read more about our key data being presented at ASH 2022.

Advancing Innovative Research Platforms

Over the last several decades, our innovative medicines have improved how blood cancer is treated, making long-term survival a possibility for more patients. But there is more work to do, and we strive to help more patients with our medicines, scientific discovery and investigational research. This year at ASH, we'll be presenting some of our most exciting data and research. Learn more about the approach that underpins this innovation.

Our pipeline at a glance >

Like any other scientific endeavor, clinical testing of novel drug compounds is a complex, extensive, resource-intensive process with no guaranteed results.  We are committed to pursuing such clinical development and, in doing so, bringing new hope to patients.

The path to a protein degrader >

Discover how Bristol Myers Squibb is building on its legacy and scientific expertise to advance the field of protein degradation and transform patient outcomes in cancer treatment.

The future of cancer care: transformative innovation for all >

Samit Hirawat, MD, executive vice president and chief medical officer, Global Drug Development, shares his perspective on the future of cancer treatment.

Pulling back the curtain on CD47 >

Learn more about the protein receptor CD47, which protects cells from being gobbled up by the human immune system, and how Bristol Myers Squibb is advancing the field of immunotherapy.

Our Leadership in Cell Therapy

Bristol Myers Squibb has a legacy of pioneering practice-changing therapies for people with cancer. Building on this heritage of innovation, our industry-leading team is pursuing a comprehensive strategy to unlock the full potential of cell therapy, a highly personalized type of immunotherapy that continues to transform the cancer treatment landscape.

Today’s cell therapy insights shaping tomorrow >

Read more to discover key insights that help us lead the way in cell therapy.

Cell therapy resources >

Discover how cell therapies are unlocking new potential in cancer research and in some of the most difficult-to-treat cancers.

Our Commitment to Hematological Cancers

At Bristol Myers Squibb, we’re centered on delivering better outcomes for all patients with blood cancers and across many hematologic conditions. However, hundreds of thousands of patients still have unmet needs for their disease. For these patients, we keep innovating. Learn more here:

Patient stories: Meet Severyne >

Severyne lives with a chronic cancer. While she knows her cancer may return, she chooses hope over fear. She looks to the positive side of her journey — meeting new people, promising treatment options and cherishing the sweet moments in her life. Hear what keeps her hopeful as she navigates life with this disease.

Explore our comprehensive approach to cancer research >

At Bristol Myers Squibb, we are driven to understand human biology and the complexities of cancer in order to advance the next generation of therapies. Our comprehensive pipeline, spanning multiple approaches across platforms and modalities, enables us to fulfill our vision of transforming patients’ lives through science.

What is myelodysplastic syndrome? Is MDS a form of cancer? >

Possibly the only thing more frightening than being diagnosed with cancer is learning that you have a form of the disease you’ve never heard of. Patients with MDS are searching for new treatment options.

Disease State and Treatment Infographics 

Download infographic resources on different types of blood cancers and therapies.